デフォルト表紙
市場調査レポート
商品コード
1426246

タンパク質阻害剤の世界市場レポート 2024

Protein Inhibitors Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
タンパク質阻害剤の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

タンパク質阻害剤の市場規模は、今後数年間で大幅に成長すると予想されます。 2028年には9.0%の年間複合成長率(CAGR)で1,252億6,000万米ドルに成長すると予想されます。今後の成長が予想されるのは、精密医療の進歩、免疫療法の注目度の高まり、薬剤の組み合わせの探索、高齢化人口のヘルスケアニーズの拡大など、さまざまな要因に関連しています。

がん、心血管疾患、自己免疫疾患などの慢性疾患の有病率が世界中で拡大しており、タンパク質阻害剤市場を大きく推進する態勢が整っています。慢性疾患は、2030年までに世界的に顕著な死亡原因となり、2020年までに米国だけで1億5,700万人に達すると予測されています。タンパク質阻害剤は、そのような疾患に対する極めて重要な治療法であり、有効性を高め、副作用を軽減します。したがって、慢性疾患に苦しむ人口の急増により、タンパク質阻害剤の需要が高まり、市場の成長に貢献すると予想されます。

個別化医療に対する需要の急増は、タンパク質阻害剤市場を推進する主要な触媒になると予想されます。個人の遺伝子構成に合わせて調整された個別化医療は、より正確で効果的な医療介入を約束します。 タンパク質阻害剤は、疾患治療のために個人の遺伝子プロファイルに合わせて特定のタンパク質を標的にすることにより、このドメインで重要な役割を果たします。注目すべきことに、2022年にFDAによって承認された新しい分子実体のかなりの割合、ほぼ34%が個別化医療のカテゴリーに該当し、そのような治療法の需要と採用の増加を示しています。この急増は、タンパク質阻害剤市場の拡大を直接推進します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のタンパク質阻害剤市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • プロテインキナーゼ阻害剤
  • モノクローナル抗体
  • その他の製品
  • 世界のタンパク質阻害剤市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 独立系薬局
  • オンライン薬局
  • 世界のタンパク質阻害剤市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 腫瘍学
  • 炎症性疾患
  • その他の用途

第7章 地域および国の分析

  • 世界のタンパク質阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のタンパク質阻害剤市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • タンパク質阻害剤市場の競合情勢
  • タンパク質阻害剤市場の企業プロファイル
    • Bayer AG
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Apotex Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r13268

Protein inhibitors are compounds that disrupt the cellular process involved in creating new proteins. They specifically target the steps in protein synthesis within cells, operating at the level of the ribosome. This is possible due to the distinct structural differences between prokaryotic and eukaryotic ribosomes.

The primary types of protein inhibitors include protein kinase inhibitors, monoclonal antibodies, and other related compounds. Monoclonal antibodies, created in laboratories, mimic or enhance the immune system's attack on unwanted cells, such as cancer cells, effectively acting as substitute antibodies. These protein inhibitors find application in treating conditions like oncology (cancer) and inflammatory diseases. They are distributed through various channels including hospital pharmacies, independent pharmacies, and online pharmacies to reach patients in need of these treatments.

The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The protein inhibitors market size has grown strongly in recent years. It will grow from $80.99 billion in 2023 to $88.74 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. Historical growth in the field of protein inhibitors can be primarily attributed to advancements in drug discovery and development, particularly in cancer treatment. Additionally, the attainment of regulatory approvals for these inhibitors played a pivotal role in their historical growth trajectory. The ongoing efforts in drug discovery and development, coupled with successful regulatory clearances, significantly contributed to the progress and expansion observed in the historic period within the domain of protein inhibitors.

The protein inhibitors market size is expected to see strongly grown in the next few years. It will grow to $125.26 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. Anticipated growth in the upcoming period is linked to various factors, including the advancement of precision medicine, the increasing prominence of immunotherapy, the exploration of drug combinations, and the expanding aging population's healthcare needs.

The expanding prevalence of chronic diseases worldwide, encompassing conditions like cancer, cardiovascular issues, and autoimmune disorders, is poised to significantly drive the protein inhibitors market. Chronic diseases are projected to become a prominent global cause of mortality by 2030, reaching an alarming 157 million cases in the US alone by 2020. Protein inhibitors stand as pivotal treatments for such diseases, offering heightened efficacy and fewer adverse effects. Hence, the burgeoning population affected by chronic ailments is anticipated to fuel the demand for protein inhibitors, contributing to market growth.

The surging demand for personalized medicine is set to be a major catalyst propelling the protein inhibitors market. Personalized medicine, tailored to an individual's genetic composition, promises more precise and effective medical interventions. Protein inhibitors play a vital role in this domain by targeting specific proteins in alignment with an individual's genetic profile for disease treatment. Notably, a significant percentage of new molecular entities approved by the FDA in 2022, almost 34% fall under the category of personalized medicines, signifying the rising demand and adoption of such treatments. This surge directly drives the expansion of the protein inhibitors market.

Companies invested in the protein inhibitors market are strategically engaging in partnerships and collaborations to drive drug development and meet market demands. Collaborative ventures and partnership agreements serve as avenues for expanding product portfolios and market presence. A prime example involves Eli Lilly and Company joining forces with Rigel Pharmaceuticals, Inc. in February 2021, entering a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, targeting autoimmune and inflammatory diseases among other indications.

Key players in the protein inhibitors market are prioritizing the development of tyrosine kinase 2 (TYK2) inhibitors, positioning themselves competitively. TYK2 inhibitors, instrumental in treating specific autoimmune conditions by blocking the TYK2 enzyme involved in immune system responses, are a significant focus. For instance, Bristol-Myers Squibb Company gained FDA approval in September 2022 for Sotyktu (deucravacitinib), an oral medication specifically for adults with moderate-to-severe plaque psoriasis eligible for systemic therapy or phototherapy. Sotyktu stands as the first oral treatment with selective inhibition of TYK2 through allosteric mechanisms, marking a significant advancement in this segment of the market.

In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus.

Major companies operating in the protein inhibitors market include Bayer AG, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Novartis International AG, GlaxoSmithKline PLC, Pfizer Inc., Boehringer Ingelheim International GmbH, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc., Interprotein Corporation, AbbVie Inc., Bristol Myers Squibb Company, Galapagos NV, Priovant Therapeutics Inc., Tempus Labs Inc., ReCode Therapeutics Inc., Satellite Bio Inc., Ambagon Therapeutics Inc., Biogen Inc., Eli Lilly and Company, Gilead Sciences Inc., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Inc., Lonza Group AG, Catalent Inc., Thermo Fisher Scientific Inc., Charles River Laboratories International Inc., WuXi AppTec Co. Ltd.

North America was the largest region in the protein inhibitors market in 2023. The regions covered in the protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Protein Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on protein inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for protein inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The protein inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product: Protein Kinase Inhibitors; Monoclonal Antibody; Other Products
  • 2) By Application: Oncology; Inflammatory Diseases; Other Applications
  • 3) By Distribution Channel: Hospital Pharmacies; Independent Pharmacies; Online Pharmacies
  • Companies Mentioned: Bayer AG; AstraZeneca plc; F. Hoffmann-La Roche Ltd.; Teva Pharmaceutical Industries Ltd.; Apotex Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Protein Inhibitors Market Characteristics

3. Protein Inhibitors Market Trends And Strategies

4. Protein Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Protein Inhibitors Market Size and Growth

  • 5.1. Global Protein Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Protein Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Protein Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Protein Inhibitors Market Segmentation

  • 6.1. Global Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Protein Kinase Inhibitors
  • Monoclonal Antibody
  • Other Products
  • 6.2. Global Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies
  • 6.3. Global Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Inflammatory Diseases
  • Other Applications

7. Protein Inhibitors Market Regional And Country Analysis

  • 7.1. Global Protein Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Protein Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Protein Inhibitors Market

  • 8.1. Asia-Pacific Protein Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Protein Inhibitors Market

  • 9.1. China Protein Inhibitors Market Overview
  • 9.2. China Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Protein Inhibitors Market

  • 10.1. India Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Protein Inhibitors Market

  • 11.1. Japan Protein Inhibitors Market Overview
  • 11.2. Japan Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Protein Inhibitors Market

  • 12.1. Australia Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Protein Inhibitors Market

  • 13.1. Indonesia Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Protein Inhibitors Market

  • 14.1. South Korea Protein Inhibitors Market Overview
  • 14.2. South Korea Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Protein Inhibitors Market

  • 15.1. Western Europe Protein Inhibitors Market Overview
  • 15.2. Western Europe Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Protein Inhibitors Market

  • 16.1. UK Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Protein Inhibitors Market

  • 17.1. Germany Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Protein Inhibitors Market

  • 18.1. France Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Protein Inhibitors Market

  • 19.1. Italy Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Protein Inhibitors Market

  • 20.1. Spain Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Protein Inhibitors Market

  • 21.1. Eastern Europe Protein Inhibitors Market Overview
  • 21.2. Eastern Europe Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Protein Inhibitors Market

  • 22.1. Russia Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Protein Inhibitors Market

  • 23.1. North America Protein Inhibitors Market Overview
  • 23.2. North America Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Protein Inhibitors Market

  • 24.1. USA Protein Inhibitors Market Overview
  • 24.2. USA Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Protein Inhibitors Market

  • 25.1. Canada Protein Inhibitors Market Overview
  • 25.2. Canada Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Protein Inhibitors Market

  • 26.1. South America Protein Inhibitors Market Overview
  • 26.2. South America Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Protein Inhibitors Market

  • 27.1. Brazil Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Protein Inhibitors Market

  • 28.1. Middle East Protein Inhibitors Market Overview
  • 28.2. Middle East Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Protein Inhibitors Market

  • 29.1. Africa Protein Inhibitors Market Overview
  • 29.2. Africa Protein Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Protein Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Protein Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Protein Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. Protein Inhibitors Market Competitive Landscape
  • 30.2. Protein Inhibitors Market Company Profiles
    • 30.2.1. Bayer AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AstraZeneca plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Teva Pharmaceutical Industries Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Apotex Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Protein Inhibitors Market Competitive Benchmarking

32. Global Protein Inhibitors Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Protein Inhibitors Market

34. Protein Inhibitors Market Future Outlook and Potential Analysis

  • 34.1 Protein Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Protein Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Protein Inhibitors Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer